Quantbot Technologies LP Purchases New Stake in TransMedics Group, Inc. $TMDX

Quantbot Technologies LP acquired a new position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 3,863 shares of the company’s stock, valued at approximately $433,000.

Other hedge funds have also made changes to their positions in the company. Vanguard Group Inc. boosted its position in TransMedics Group by 0.3% during the 3rd quarter. Vanguard Group Inc. now owns 3,605,607 shares of the company’s stock worth $404,549,000 after purchasing an additional 9,650 shares during the period. Geode Capital Management LLC grew its stake in shares of TransMedics Group by 1.4% in the second quarter. Geode Capital Management LLC now owns 804,650 shares of the company’s stock valued at $107,845,000 after buying an additional 11,241 shares in the last quarter. Marshall Wace LLP raised its holdings in shares of TransMedics Group by 258.7% during the 2nd quarter. Marshall Wace LLP now owns 546,787 shares of the company’s stock valued at $73,275,000 after buying an additional 394,340 shares during the period. Goldman Sachs Group Inc. lifted its position in TransMedics Group by 20.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 507,510 shares of the company’s stock worth $34,145,000 after acquiring an additional 86,721 shares in the last quarter. Finally, Zevenbergen Capital Investments LLC boosted its holdings in TransMedics Group by 112.7% in the 3rd quarter. Zevenbergen Capital Investments LLC now owns 258,523 shares of the company’s stock worth $29,006,000 after acquiring an additional 136,995 shares during the period. Hedge funds and other institutional investors own 99.67% of the company’s stock.

TransMedics Group Stock Performance

TMDX stock opened at $134.77 on Tuesday. The stock’s 50 day simple moving average is $135.58 and its 200 day simple moving average is $127.08. TransMedics Group, Inc. has a 12-month low of $62.23 and a 12-month high of $156.00. The firm has a market cap of $4.62 billion, a P/E ratio of 27.50 and a beta of 1.98. The company has a current ratio of 7.14, a quick ratio of 6.59 and a debt-to-equity ratio of 1.06.

Insider Activity at TransMedics Group

In other news, CFO Gerardo Hernandez sold 7,236 shares of the firm’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $147.21, for a total value of $1,065,211.56. Following the transaction, the chief financial officer directly owned 14,689 shares in the company, valued at approximately $2,162,367.69. This trade represents a 33.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Anil P. Ranganath sold 864 shares of TransMedics Group stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $139.12, for a total transaction of $120,199.68. Following the completion of the transaction, the insider directly owned 13,091 shares of the company’s stock, valued at $1,821,219.92. This trade represents a 6.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 16,205 shares of company stock valued at $2,353,002 in the last ninety days. 7.00% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on TMDX. Canaccord Genuity Group boosted their target price on shares of TransMedics Group from $147.00 to $148.00 and gave the stock a “buy” rating in a research report on Wednesday, December 17th. Stifel Nicolaus raised their target price on TransMedics Group from $115.00 to $130.00 and gave the company a “hold” rating in a research note on Monday. Oppenheimer boosted their price target on TransMedics Group from $150.00 to $175.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 25th. Needham & Company LLC raised their price objective on TransMedics Group from $166.00 to $174.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Finally, Piper Sandler upped their target price on TransMedics Group from $140.00 to $160.00 and gave the company an “overweight” rating in a research report on Wednesday, February 25th. Six equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $152.33.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.